OncoTelic Overview
- Founded
-
2015
- Status
-
Public
- Employees
-
16
- Stock Symbol
-
OTLC
- Investments
-
2
- Share Price
-
$0.06
- (As of Wednesday Closing)
OncoTelic General Information
Description
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
PINX
Primary Office
- 29397 Agoura Road
- Suite 107
- Agoura Hills, CA 91301
- United States
+1 (650) 000-0000
OncoTelic Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.06 | $0.06 | $0.05 - $0.26 | $24.9M | 386M | 248K | $0.03 |
OncoTelic Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 74,532 | 70,203 | 21,907 | 14,796 |
| Revenue | 0 | 0 | 1,741 | 0 |
| EBITDA | 9,538 | (8,453) | (7,609) | (5,828) |
| Net Income | 7,806 | (9,391) | (9,503) | (6,638) |
| Total Assets | 40,388 | 23,613 | 23,663 | 23,685 |
| Total Debt | 9,802 | 8,993 | 4,653 | 1,501 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
OncoTelic Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
OncoTelic Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatme
Biotechnology
Agoura Hills, CA
16
As of 2021
00.00
000000000
00.00
000000
olore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui of
0000 000000000
San Carlos, CA
00
As of 0000
00000
000000000
00000
000000
rcitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehen
0000 000000000
Palo Alto, CA
00
As of 0000
00000
0000000000
00000
Add Comparison
OncoTelic Competitors (4)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Apexigen | Formerly VC-backed | San Carlos, CA | 00 | 00000 | 000000000 | 00000 |
| 000000-000 0000000 | Venture Capital-Backed | Palo Alto, CA | 00 | 00000 | 0000000000 | 00000 |
| 00000 00000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
OncoTelic Executive Team (15)
OncoTelic Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Anthony Maida Ph.D | Self | Chief Clinical Officer - Translational Medicine | 000 0000 |
| Frederick Driscoll | Self | Chief Executive Officer & Board Member | 000 0000 |
OncoTelic Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
OncoTelic Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
OncoTelic Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000 000000000 | 31-Mar-2022 | 00000 0000 | Drug Discovery | 00000 000 | |
| Mateon Therapeutics | 25-Apr-2019 | Merger/Acquisition | Drug Discovery | 00000 000 |